SEC Filing Analysis: SELECT MEDICAL HOLDINGS CORP (SEM)

Executive Summary

• Trading Significance: Low
• Key Takeaway: John F. Duggan, an Executive Vice President at Select Medical, was awarded 50,000 restricted shares as part of his compensation package, with a four-year vesting period.
• Market Impact: The grant represents a minor 0.04% dilution to shareholders and is not an open-market transaction, indicating a neutral short-term market impact.

Company Information

Field	Value
Company	SELECT MEDICAL HOLDINGS CORP
Ticker Symbol	SEM
CIK	0001320414
Industry	SERVICES-HOSPITALS

Insider Information

Field	Value
Name	Duggan John F.
CIK	0002081450
Title/Position	Executive Vice President
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-28
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	50,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	199,575
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	50,000
% of Shares Outstanding	0.040%
Post-Transaction Ownership	199,575 shares (0.161% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction has a value of $0 and is therefore immaterial against the company's $1.77 billion market capitalization.
• Ownership Concentration: After the grant, the insider's ownership increases to 199,575 shares, which constitutes a modest 0.161% of total shares outstanding. This does not represent a significant concentration of ownership.
• Dilution Impact: The 50,000 new shares awarded represent a 0.040% dilution to existing shareholders. This is a very low level of dilution, typically considered routine for executive compensation in a company of this size.
• Transaction Significance: The transaction's significance is low. It is not an open-market purchase or sale reflecting insider sentiment on the stock's current valuation. Instead, it is a pre-planned compensation event designed to retain and incentivize an executive.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: As a non-cash, pre-scheduled compensation grant, this transaction does not signal new information about the company's prospects. The market typically does not react to such routine filings.

Volume & Sentiment

• Expected Volume Impact: Negligible. No market transaction occurred.
• Sentiment Indicator: Neutral. This filing is informational regarding executive compensation and does not carry a bullish or bearish signal.

Investment Insights

Positive Market Indicators

• The grant aligns the executive's interests with shareholders over a long-term (4-year) vesting period.

Risk Factors

• While minor in this case, investors should monitor the cumulative effect of equity grants on overall shareholder dilution over time.

Key Takeaways

1. An EVP was granted 50,000 restricted shares, a standard form of equity compensation.
2. The transaction has a negligible financial impact, causing only a 0.04% dilution to shares outstanding.
3. This is not a market trade and carries no immediate signal regarding the insider's view on the stock's valuation.

Additional Context

Transaction Notes

• Special Circumstances: The filing footnote specifies this is a grant of restricted stock that will vest in full on the fourth anniversary of the grant date, October 28, 2029.